Summary Plan Description (SPD)

The Summary Plan Description (SPD) is a crucial document within the context of an employer-sponsored 401(k) retirement plan. It serves as a comprehensive overview of the plan's key features, rules, and benefits, presented in a clear and understandable manner for plan participants. The SPD is mandated by the Employee Retirement Income Security Act (ERISA) and acts as a vital communication tool between the plan administrator and employees.

 

The SPD encompasses various essential components that participants need to grasp, such as eligibility criteria, vesting schedules, contribution limits, investment options, and distribution rules. It outlines the responsibilities of both the employer and plan participants, ensuring transparency and compliance with legal requirements.

 

Example 1: John, a new employee, recently joined a company offering a 401(k) plan. He receives the SPD, which explains that he becomes eligible to enroll in the plan after six months of employment and the employer matches 50% of his contributions up to 6% of his salary.

 

Example 2: Jane, a long-time employee, decides to rollover her previous employer's 401(k) into her current company's plan. The SPD clarifies the rollover process, associated fees, and investment options available.

 

Example 3: Mark is considering taking a loan from his 401(k) to cover an emergency expense. Before proceeding, he reviews the SPD to understand the loan terms, repayment schedule, and potential implications on his retirement savings.

 

In essence, the Summary Plan Description is an indispensable guide that empowers employees to make informed decisions about their retirement savings and ensures the employer's adherence to ERISA regulations.

Next Up

Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.
Most U.S. employers now offer paid maternity leave beyond the legal minimum, but coverage varies widely once you look past the basics. According to Mployer Insights' 2026 analysis of more than 50,000 employer benefit plans, 68% of employers provide paid maternity leave on top of short-term disability, typically adding 8 extra weeks, and half now cover 100% of salary during the disability period. Support drops off from there: only 41% of employers offer paid bonding leave for non-birth parents, and advanced family-building benefits remain even less common, with just 28% covering IVF and 11% offering adoption financial assistance. The data suggests that while baseline maternity leave has become standard, more comprehensive family-building support is still the exception rather than the norm.